MedWatch

Analyst: Potential Apple product could target GN's market segment

According to Janne Vincent Kjær, senior equity analyst at Jyske Bank, it is most likely that a new Apple product would be aimed at people suffering mild hearing loss – which is the same target group of GN's Jabra Enhance Plus.

On Wednesday afternoon, hearing aid manufacturers GN and Demant's share prices dropped on OMX Copenhagen 25, after rumors began to spread that Apple is investigating whether its Airpods product can be used as a solution for hearing health. The rumors were reported by the Wall Street Journal, referring to sources it says are familiar with Apple's plans.

It is not readily apparent if Apple wants to develop new, specific hearing device functions for the Airpods, or if the tech giant is seeking to brand the earbuds' existing hearing enchancing features as hearing aid functions.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs